GB201309636D0 - Method of screening a drug such as insulin secretagogue - Google Patents

Method of screening a drug such as insulin secretagogue

Info

Publication number
GB201309636D0
GB201309636D0 GBGB1309636.7A GB201309636A GB201309636D0 GB 201309636 D0 GB201309636 D0 GB 201309636D0 GB 201309636 A GB201309636 A GB 201309636A GB 201309636 D0 GB201309636 D0 GB 201309636D0
Authority
GB
United Kingdom
Prior art keywords
screening
drug
insulin secretagogue
transformant
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB1309636.7A
Other versions
GB2503105B (en
GB2503105A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JNC Corp
Original Assignee
JNC Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JNC Corp filed Critical JNC Corp
Publication of GB201309636D0 publication Critical patent/GB201309636D0/en
Publication of GB2503105A publication Critical patent/GB2503105A/en
Application granted granted Critical
Publication of GB2503105B publication Critical patent/GB2503105B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
GB1309636.7A 2009-03-16 2010-03-12 Method of screening a drug such as an MMP-2 secretagogue Active GB2503105B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009063279A JP5572972B2 (en) 2009-03-16 2009-03-16 Screening method for drugs such as insulin secretagogues
GB1004167.1A GB2468757B (en) 2009-03-16 2010-03-12 Method of screening a drug such as insulin secretagogue

Publications (3)

Publication Number Publication Date
GB201309636D0 true GB201309636D0 (en) 2013-07-17
GB2503105A GB2503105A (en) 2013-12-18
GB2503105B GB2503105B (en) 2014-08-27

Family

ID=42261505

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1004167.1A Active GB2468757B (en) 2009-03-16 2010-03-12 Method of screening a drug such as insulin secretagogue
GB1309636.7A Active GB2503105B (en) 2009-03-16 2010-03-12 Method of screening a drug such as an MMP-2 secretagogue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB1004167.1A Active GB2468757B (en) 2009-03-16 2010-03-12 Method of screening a drug such as insulin secretagogue

Country Status (3)

Country Link
US (3) US9181318B2 (en)
JP (1) JP5572972B2 (en)
GB (2) GB2468757B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5764921B2 (en) 2009-12-24 2015-08-19 Jnc株式会社 Fusion protein with luminescent activity
MX361861B (en) 2011-11-07 2018-12-18 Broad Inst Inc Propeptide-luciferase fusion proteins and methods of use thereof.
EP3506945A4 (en) * 2016-08-30 2020-07-15 Board of Regents, The University of Texas System Production of seleno-biologics in genomically recoded organisms
JP7016865B2 (en) * 2016-09-02 2022-03-03 イントレクソン・アクトバイオテイクス・エヌブイ Gene-modified bacteria that stably express IL-10 and insulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6228604B1 (en) * 1996-04-10 2001-05-08 Loma Linda University Secreted renilla luciferase
EP1875927B1 (en) * 1997-12-17 2011-10-26 The General Hospital Corporation Methods for evaluating a compound for its effect on skin
EP1064360B1 (en) * 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
US7250406B2 (en) * 2002-04-19 2007-07-31 Georgia Tech Research Corporation Compositions and methods for the acceleration of protein secretion dynamics
WO2005037226A2 (en) * 2003-10-17 2005-04-28 Georgia Tech Research Corporation Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders
GB2442118B (en) * 2006-09-19 2011-08-17 Chisso Corp Process for production of recombinant proteins as a soluble form
JP5347255B2 (en) * 2006-09-19 2013-11-20 Ｊｎｃ株式会社 Method for producing recombinant protein as soluble protein
TW200923102A (en) * 2007-07-17 2009-06-01 Gen Hospital Corp Matrix metalloprotease targeting nucleic acids
WO2012171024A2 (en) * 2011-06-10 2012-12-13 The Regents Of The University Of California Enzyme directed assembly of particle theranostics

Also Published As

Publication number Publication date
US20100240038A1 (en) 2010-09-23
JP5572972B2 (en) 2014-08-20
GB2468757A (en) 2010-09-22
US9835615B2 (en) 2017-12-05
GB2503105B (en) 2014-08-27
US20180011082A1 (en) 2018-01-11
JP2010213610A (en) 2010-09-30
GB2468757B (en) 2014-08-20
US9181318B2 (en) 2015-11-10
US20160011173A1 (en) 2016-01-14
US10393732B2 (en) 2019-08-27
GB201004167D0 (en) 2010-04-28
GB2503105A (en) 2013-12-18

Similar Documents

Publication Publication Date Title
MX340498B (en) Heterodimerized polypeptide.
MY180714A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
MX2018013981A (en) Improved peptide pharmaceuticals for insulin resistance.
MY159135A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP2195331A4 (en) Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
IN2012DN02120A (en)
MX355041B (en) Non-natural consensus albumin binding domains.
MX2011013903A (en) Chimeric fgf19 polypeptides and uses thereof.
NZ596735A (en) Recombinant production of peptides
IN2012DN00908A (en)
MX2019004487A (en) Methods and compositions for the treatment of fabry disease.
JO3026B1 (en) Peptidic glp-2 agonists
EP2569017A4 (en) Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
MX342171B (en) Peptide or peptide complex binding to 2 integrin and methods and uses involving the same.
GB201309636D0 (en) Method of screening a drug such as insulin secretagogue
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
PL3736329T3 (en) Consumable cryopreserved cells transiently overexpressing gene(s) encoding drug transporter protein(s) and/or drug metabolizing enzyme(s)
GB201211617D0 (en) Production of cyclic peptides
MX366347B (en) Isolating traffic-enhancing mutants of drug delivery protein.
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
EP2128252A4 (en) Fused protein containing insulin precursor of overexpression and secretion type, dna encoding the same and method of producing insulin
ZA201200046B (en) Therapeutic peptides, polypeptides and nucleic acid sequences